Small molecule · Inhibitor of Focal adhesion kinase (FAK) (PTK2) · developed by Verastem
Defactinib is an orally bioavailable small-molecule inhibitor of focal adhesion kinase (FAK) and Pyk2, two nonreceptor tyrosine kinases of the FAK family. It inhibits FAK autophosphorylation, which may block integrin-mediated signaling through RAS/MEK/ERK and PI3K/Akt. It is studied in ovarian cancer, lung cancer, and metastatic uveal melanoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 1, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06072781 | Phase 3 | Low Grade Serous Ovarian Cancer | Recruiting | VSTM |
| NCT04720417 | Phase 2 | Metastatic Uveal Melanoma | Terminated | VSTM |
| NCT03287271 | Phase 1/2 | Ovarian Cancer | Terminated | VSTM |
| NCT01951690 | Phase 2 | Non Small Cell Lung Cancer | Completed | VSTM |
| NCT02943317 | Phase 1 | Epithelial Ovarian Cancer | Terminated | VSTM |
| NCT00787033 | Phase 1 | Cancer | Completed | VSTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Low Grade Serous Ovarian CancerCancerEpithelial Ovarian CancerLung CancerMetastatic Uveal MelanomaNon Small Cell Lung CancerOvarian Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the VSTM page.
See VSTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VSTM catalysts and pipeline →